Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 8INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Dermatologic 1

Conditions

Solid Tumor 1Neoplasms 1Melanoma 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × HuMax-IL8 × Clear all
NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Bristol-Myers Squibb

Phase 1/2 Completed
281 enrolled 44 charts
Dermatologic

Melanoma, Neoplasms

NCT02536469 2017-02-03

HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
15 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡